150428-54-9

Usage

InChI:InChI=1/C27H37N3O2/c1-6-16-29-18-21(5)30(19-20(29)4)26(24-10-9-11-25(31)17-24)22-12-14-23(15-13-22)27(32)28(7-2)8-3/h6,9-15,17,20-21,26,31H,1,7-8,16,18-19H2,2-5H3/t20-,21+,26-/m1/s1

Upstream product

• 58287-77-7 N,N-diethyl-4-formylbenzamide 
• 117973-14-5 3-(tert-butyldimethylsilyloxy)phenylmagnesium bromide 
• 155836-78-5 (-)-(2R,5S)-1-allyl-2,5-dimethylpiperazine 
• 619-66-9 4-Carboxybenzaldehyde 
• 155765-75-6 4-[(3-{[tert-butyl(dimethyl)silyl]oxy}phenyl)(hydroxy)methyl]-N,N-diethylbenzamide 
• 65423-56-5 1-bromo-3-[(tert-butyldimethylsilyl)oxy]benzene 
• 591-20-8 3-Bromophenol 
• 186094-06-4 (±)-4-[hydroxy-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide 
• 156727-77-4 N,N-diethyl-4-(3-methoxybenzoyl)benzamide 
• 156727-76-3 4-(3-methoxybenzoyl)benzoic acid 
• 1027905-05-0 4-(3-Methoxy-benzoyl)-benzoyl chloride 
• 108-88-3 toluene 
• 1711-05-3 m-anisoyl chloride 
• 82520-37-4 (4-methylphenyl)-(3-methoxyphenyl)methanone 

Relevant academic research and scientific papers

DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE

The present invention provides for compositions and methods for the treatment of Parkinson's disease comprising a compound of formula (i): or a pharmaceutically effective salt or ester thereof alone or in combination with L-DOPA to provide a synergistic e

OLIGOMER-DIARYLPIPERAZINE CONJUGATES

The invention relates to (among other things) oligomer-diarylpiperazine conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated diarylpiperazine compounds.

METHOD OF TREATING PARKINSON'S DISEASE WITH DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA RECEPTOR AGONIST ACTIVITY

Compositions and methods for treatment of Parkinson's disease to reduce the negative side effects of the disease by administering a therapeutically effective diarylmethylpiperazine compound which exhibits delta opioid receptor agonist activity, and option

Method of treating sexual dysfunctions with delta opioid receptor agonist compounds

Compositions and methods for treatment of sexual dysfunctions by administering to a subject a pharmaceutical composition comprising a delta opioid receptor agonist in an amount effective to delay the onset of ejaculation in the subject during sexual stimulation.

Compositions and Methods for Reducing Respiratory Depression and Attendant SIde Effects of Mu Opioid Compounds

A method of reducing, treating or preventing drug-mediated respiratory depression, muscle rigidity, or nausea/vomiting in an animal, incident to the administration to said animal of a mixed delta/mu opioid agonist or a respiratory depression-mediating dru

Compositions and methods for reducing respiratory depression

The present invention relates to, inter alia, methods and compositions for reducing, treating or preventing respiratory depression in an animal, using a compound of the formula: STR1 wherein: Ar, G, Z, R2, R3, R4, R5

Probes for narcotic receptor mediated phenomena. 23. Synthesis, opioid receptor binding, and bioassay of the highly selective δ agonist (+)-4- [(αR)-α-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]N,N- diethylbenzamide (SNC 80) and related novel nonpeptide δ opioid receptor ligands

The highly selective delta (δ) opioid receptor agonist SNC 80 [(+)-4- [(αR)-α-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N- diethylbenzamide, (+)-21] and novel optically pure derivatives were synthesized from the enantiomers of 1-allyl-trans-2,5-dimethylpiperazine (2). The piperazine (±)-2 was synthesized, and its enantiomers were obtained on a multigram scale in >99% optical purity by optical resolution of the racemate with the camphoric acids. The absolute configuration of (+)-2 was determined to be 2S,5R by X-ray analysis of the salt with (+)-camphoric acid. Since the chirality of the starting material was known, and the relative configuration of compounds (-)-21, (-)-22, and (+)-23 were obtained by single-crystal X- ray analysis, the assignment of the absolute stereochemistry of the entire series could be made. Radioreceptor binding studies in rat brain preparations showed that methyl ethers (+)-21 (SNC 80) and (-)-25 exhibited strong selectivity for rat δ receptors with low nanomolar affinity to 6 receptors and only micromolar affinity for rat mu (μ) opioid receptors. Compounds (- )-21, (-)-22, and (-)-23 showed micromolar affinities for δ opioid receptors. The unsubstituted derivative (+)-22 and the fluorinated derivative (-)-27 showed >2659- and >2105-fold δ/μ binding selectivity, respectively. The latter derivatives are the most selective ligands described in the new series. Studies with some of the compounds described in the isolated mouse vas deferens and guinea pig ileum bioassays revealed that all were agonists with different degrees of selectivity for the δ opioid receptor. These data show that (+)-21 and (+)-22 are potent δ receptor agonists and suggest that these compounds will be valuable tools for further study of the δ opioid receptor at the molecular level, including its function and role in analgesia and drug abuse.